Neurotech Completes Enrollment in Three Studies
Neurotech Pharmaceuticals has completed enrollment in three studies, each of which will evaluate NT-501 for retinitis pigmentosa (RP) or the dry form of age-related macular degeneration (AMD).
RP is an inherited disease causing the retina’s rod and cone photoreceptors to degenerate. AMD is a chronic progressive disease of the macula that results in the loss of central vision.
The randomized, multicenter, double-masked, sham-controlled Phase II/III study is evaluating NT-501 in 60 subjects with early-stage RP. Each subject will receive either a high or low dose NT-501 implant in one eye and a sham treatment in the other. Visual field sensitivity is the primary efficacy endpoint of this study.
A second Phase II/III study will evaluate 60 subjects with late-stage RP. Each subject will receive either a high or low dose NT-501 implant in one eye and a sham treatment in the other. Visual acuity is the primary efficacy endpoint.
A Phase II study will evaluate 48 subjects with dry AMD. Each subject will receive either a high or low dose NT-501 implant or a sham treatment in one eye only. Visual acuity is the primary efficacy endpoint, Neurotech said.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May